American Journal of Hematology

Article	Citations
Issue Information	456
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	261
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	227
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	154
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	146
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	146
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	141
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	131
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	126
	107
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	95
CORRIGENDUM	85
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	83
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	81
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	76
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	74
Are veterans at increased risk of myeloproliferative neoplasms?	71
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	70
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	69
Acute thrombocytopenia suggesting thrombotic microangiopathy	66
	65
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	63
The latest insights into rare blood disorders: Diagnosis and treatment strategies	61
Muscular de‐conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major	60
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	60

Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	59
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	59
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	56
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	55
Teclistamab in patients with multiple myeloma and impaired renal function	55
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	53
Ruxolitinib for refractory large granular lymphocyte leukemia	52
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	50
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	49
Clonal Hematopoiesis and Thrombosis	47
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	46
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	46
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	45
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	44
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	44
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	43
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	43
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	43
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	42
Table of Contents	42
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	42
Molecular and clinicopathologic characterization of pediatric histiocytoses	42
International Consensus Classification for myeloid neoplasms at‐a‐glance	41
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	41
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis	41
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (	39
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	38
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource	37
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	37
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)	36
Hydroxyurea in pregnancy: Reframing the conversation	35
	35
POEMS syndrome: Update on diagnosis, risk‐stratification, and management	35
Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation	35
A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort	35
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	34
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurre	34
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	34
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases	34
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants	34
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy	34
Rare circulating lymphoblasts with striking eosinophilia: A rare case of B‐lymphoblastic leukemia with PAX5::ZCCHC7	33
Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population‐based study	33
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort	33
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	32
Peak absolute lymphocyte count after CAR‐T infusion predicts clinical response in aggressive lymphoma	32
Novel, de novo, beta‐globin variant with decreased oxygen affinity (HBB:c.317T>A, “Hemoglobin St. George”) in a healthy child with low oxygen saturations and ane	31
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	31
Impaired pro‐resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease	31
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease‐positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial	31

Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients	30
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	29
Toward an improved understanding of hypomethylating agent and venetoclax therapies	29
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study	29
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficien	29
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β0 Thalassemia Major Patient	29
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring	28
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation	28
Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors: A Machine Learning Approach	28
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	28
Pearson syndrome	28
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)	28
Elevated MCHC reveals a Southeast Asian Ovalocytosis	28
Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia—aCML)	27
Prognostic impact of KMT2A‐AFF1‐positivity in 926 BCR‐ABL1‐negative B‐lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials sin	27
ERRATUM	27
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort	27
Myelokathexis in an 18‐year‐old male patient with severe neutropenia and lymphopenia	27
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results	26
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia	26
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia	26
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy	26
The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1: A 10‐year retrospective study	26
Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes	26
Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis	26
A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia	26
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis	25
Issue Information	25
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study	25
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells	25
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors	25
A case of peripheral T‐cell lymphoma, NOS, mimicking acute monocytic leukemia	25
The Diversity of Spiculated Erythrocytes	25
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants	25
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?	25
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study	25
Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type	24
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria	24
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy	24
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial	24
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia	24
Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers	24
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma	24
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma	24
Tissue factor activity is increased in neutrophils from JAK2 V617F‐mutated essential thrombocythemia and polycythemia vera patients	23
Transient receptor potential channel vanilloid type 2 in red cells of cannabis consumer	23
TACI variants as underlying condition in autoimmune neutropenia: Description of four cases	23
PF‐07059013: A non‐covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease	23
Primary myelofibrosis in a patient with sickle cell disease	23
A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic	23
LLM Abstracts Supplement	23
Hemolytic anemia and macrothrombocytopenia: A lipid problem?	23
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies	22
Thirteen‐month‐old girl with hyporegenerative macrocytic anemia due to Brown–Vialetto–Van Laere syndrome 2	22
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	22
Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma	22
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort Study	22
Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study	22
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	22
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B‐Cell Lymp	22
Table of Contents	21
SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey	21
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph‐positive leukemias	21
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management	21
Unusual complications in the management of chronic lymphocytic leukemia	21
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	21
Issue Information	20
Peripheral CD5+ CD10+ B‐cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation	20
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma	20
Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis	20
Myopathy related to chronic Graft‐Versus‐Host Disease: From clinic to histological & immunological characterization by imaging mass cytometry	20
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study	20
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation	20
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis	20
SARS‐CoV‐2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor	19
Multiple thrombosis in a patient with Gardos channelopathy and a new KCNN4 mutation	19
The pleiotropic effects of α‐thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co‐transport activity, serum erythropoietin, and transfusion burden, do	19
Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients	19
Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma	19
	19

Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing	19
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia	19
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms	19
Disseminated coccidioidomycosis in bone marrow	19
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept	19
Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial	19
‘Phenoconversion’ in adult patients with β‐thalassemia	19
Generating Off‐the‐Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells	18
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition	18
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases	18
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers	18
The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial	18
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia	18
2025 update on clinical trials in immune thrombocytopenia	18
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial	18
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated mult	18
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial	18
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?	17
RETRACTION: A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation	17
Space anemia unexplained: Red blood cells seem to be space‐proof	17
Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia	17
High incidence of malaria in patients with sickle cell disease	17
Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study	17
Issue Information	17
Table of Contents	17
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by	17
ALK‐positive histiocytosis of external auditory canal in a 3‐year‐old boy	17
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?	17
A 29‐gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival	17
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma	17
Peripheral blood evidence of iron overload	17
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma	17
A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa	17
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort	17
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invader	16
Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy	16
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan	16
Hyperparathyroidism and the Hematologist	16
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies	16
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA	16
Nobel prize in physiology or medicine 2021, receptors for temperature and touch: Implications for hematology	16
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients	16
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials	16
Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia	16
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study	16
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study	16
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management	16
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies	16
Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease	16
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	16
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single‐arm, phase	16
Management of post‐autologous transplant relapse in patients with T‐cell lymphomas	16
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?	15
Characterization of the human ABO genotypes and their association to common inflammatory and cardiovascular diseases in the UK Biobank	15
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	15
Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?	15
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria	15
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or	15
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	15
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes	15
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	15
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple	15
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukem	15
Complement biology for hematologists	15
Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features	15
	14
	14
	14
	14
Issue Information	14
Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7‐targeted Chimeric Antigen R	14
Crystal‐storing lymphocytosis	14
Rate of major bleeding with ibrutinib versus bendamustine‐rituximab in chronic lymphocytic leukemia: A population‐based cohort study	14
Increased risk of venous thromboembolism in patients with gastrointestinal disorders	14
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment	14
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases	14
Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators	14
Correction to “Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis”	14
	14
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	14
	14
Fulminant intravascular hemolysis resulting from Clostridium perfringens infection	14
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms	14
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy	14
Thalassemia enters a new age … And more lies ahead	14
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort	13
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study	13
Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia	13
Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study	13
Molecular and clinical characterization of transient antithrombin deficiency: A new concept in congenital thrombophilia	13
How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria	13
Changing hemostatic management in post‐partum hemorrhage	13
Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable	13
DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1	13
Phase II clinical trial of one dose of post‐transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched‐unrelated donor	13